Enumeral Biomedical Holdings Inc fka ENUMQ

[maverick_1]

NAILS in the COFFIN: Why MB's are for the needy, inexperienced or EGO's trampled by INVESTMENT REALITIES: good to point out academic viewpoints but clear inability to make crucial investment decisions.

http://www.biospace.com/News/cash-strapped-enumeral-biomedical-cuts-rd-staff/460398/source=TopBreaking

http://www.bizjournals.com/boston/news/2017/05/26/cambridge-biotech-enumeral-faces-uncertain-future.html

WARREN PATTERSON

Cambridge cancer drug developer Enumeral could be forced to downsize, file for bankruptcy or sell its assets unless it quickly raises additional capital, the company said this week.

Enumeral (OTCQB: ENUM), a 10-employee company whose stock is traded over the counter, said in a press release Monday that it had $1.4 million in cash as of the end of March. Following a recent private placement that netted $548,000, the company said it can fund its operations “only into June 2017."

Amid the cash crunch, Enumeral said it is “exploring a range of potential transactions.” According to the company, that could include a public or private offering, debt financing, collaborations and licensing deals, or a potential merger or asset sale.

MORE $ DOWN THE DRAIN following others: complacency vs vigilance of being on top of it

DIFFERENT STROKES FOR DIFFERENT FOLKS